Galmed amends AGM proxy materials ahead of Sept. 2 shareholder vote

• Galmed filed an amended proxy statement dated Aug. 19, 2026 for its Sept. 2 annual meeting.
• Shareholders will vote on re-electing two directors, a new compensation policy, revised director pay, auditor reappointment.
• Key amendment seeks to eliminate ordinary-share par value, reset authorized capital to 900,000,000 no-par-value shares, rename the company Eocene Ltd.
• Name and par-value proposal requires 75% shareholder support; other proposals need a simple majority, with special vote thresholds for compensation items.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galmed Pharmaceuticals Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-039207), on August 19, 2026, and is solely responsible for the information contained therein.